Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

News Daily News

Meta-analysis Affirms Colchicine’s Myriad CV Benefits

Caitlin E. Cox

April 12, 2021

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Industry News

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

May 26, 2017

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Todd Neale

March 14, 2015

Advertisement

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

FDA Approves Colchicine for Decreasing CV Events

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Meta-analysis Affirms Colchicine’s Myriad CV Benefits

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

No Benefit of Colchicine in All-Comers PCI

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content